Skip to main content
Signal8

Accustem Sciences Inc. (ACUT) Form 10-Q — May 15, 2026

$ACUTForm 10-QFiled May 15, 2026, 4:05 PM ET0001493152-26-023742Original filing

AccuStem Sciences Inc. reported a net loss of $485,883 for the quarter ended March 31, 2026, driven by increased R&D expenses of $119,525 for its MSC and StemPrintER diagnostic tests. The company has no revenue and holds only $12,207 in cash against total liabilities of $5.4 million, including a $4.7 million payable to related party Tiziana. Management disclosed a material weakness in internal controls over financial reporting due to a lack of accounting resources and inadequate segregation of duties.

Key figures

Revenue
0
Total Debt
5421879
Total Assets
1549532
Cash Position
12207
Shares Outstanding
16072267
Rd expenses q1 2026
119525
G a expenses q1 2026
366358
Related party payable
4682455
Unrecognized compensation expense
436360

Price after filing

1 day: 0.0%7 days: +3.5%30 days: -1.9%

Close on the filing date to close N calendar days later (from $0.26). Historical, not a forecast.

AI analysis

Red flags5 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.